BHEKISISA: Bringing it home: SA leads the charge to make

South Africa is positioning itself as a global hub for affordable HIV therapeutics, with the National Aids Council (NAC) launching an aggressive strategy to secure compulsory licences for locally-manufactured generic lenacapavir. This move represents a watershed moment for European pharmaceutical investors seeking exposure to Africa's $15bn+ annual healthcare market—and a critical test case for how intellectual property frameworks will evolve across the continent.

Lenacapavir, developed by Gilead Sciences, is a breakthrough long-acting HIV capsid inhibitor requiring only two injections annually, compared to daily oral regimens. The drug represents the first-in-class advancement in HIV treatment in nearly a decade, with potential to dramatically improve treatment adherence in sub-Saharan Africa, where pill burden remains a significant barrier to viral suppression. South Africa's NAC is pursuing compulsory licensing under its amended Patent Act, enabling domestic manufacturers to produce generic versions without Gilead's consent—a legally permitted pathway under the TRIPS agreement.

The economic case is compelling. HIV prevalence in South Africa stands at 7.2% of the adult population, translating to approximately 2.4 million people living with HIV. Gilead's anticipated pricing for lenacapavir globally ranges from $35,000-$42,000 annually—prohibitive for most sub-Saharan markets. Generic alternatives could reduce cost-of-treatment to $500-$1,200 per patient annually, fundamentally reshaping HIV programme economics across the region. For European investors, this signals a €1.2bn+ addressable market opportunity across Southern Africa alone within five years.

The strategic implications extend beyond HIV therapeutics. South Africa's pharmaceutical sector already dominates African generic production, accounting for roughly 40% of the continent's pharmaceutical manufacturing capacity. A successful compulsory licence for lenacapavir would establish regulatory precedent, potentially triggering similar licensing demands for oncology, diabetes, and cardiovascular drugs where European manufacturers hold key patents. This creates both opportunity and regulatory risk.

European pharmaceutical companies should view this development through three lenses. First, licensing partners: local South African manufacturers (Aspen Pharmacare, Cipla) will require technology transfer and quality assurance partnerships, creating acquisition or joint-venture entry points for European capital. Second, distribution networks: successful generic lenacapavir production requires sophisticated cold-chain logistics and hospital-level procurement systems—areas where European health-tech firms have competitive advantage. Third, regulatory arbitrage: investors should monitor how compulsory licensing decisions affect intellectual property frameworks across SADC member states, which collectively represent 370 million people.

The timeline matters. NAC is targeting manufacturing commencement within 18-24 months. European investors entering now can shape manufacturing partnerships, secure distribution rights, or develop complementary diagnostic and adherence-tracking technologies before market entry accelerates. However, Gilead's response remains unpredictable—the company has challenged similar licensing attempts in India and could initiate costly legal proceedings.

This represents a rare convergence: a regulatory shift aligned with humanitarian need, massive unmet market demand, and clear pathways for European capital deployment in pharmaceutical manufacturing, logistics, and health technology across Africa's largest economy.